Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for unmet medical needs in the United States. Its zinc finger DNA-binding proteins (ZFPs) could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways for genome editing and gene regulation; and ZFP transcription factors (ZFP TFs) proteins could be used to turn genes on or off. The companys principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops CERE-110 that is in Phase II clinical trial for the treatment of Alzheimers disease. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, huntingtons disease, and hemoglobinopathies; and proprietary programs in the areas of lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including various immunodeficiencies, as well as central nervous system disorders and cancer immunotherapy. The company has collaboration and license agreements with Shire International GmbH and Biogen Idec Inc.; and strategic partnerships with Sigma-Aldrich Corporation, Dow AgroSciences, LLC, Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.
January 20, 2017
RegMed Investors’ (RMi) closing bell analysis, a new tide of shareholder populism is about to kick-off
January 19, 2017
RegMed Investors’ (RMi) closing bell analysis, value keeps slippin’ and sliding from the sector
January 18, 2017
RegMed Investors’ (RMi) closing bell analysis, short-term oversold conditions continue to challenge the sector
January 17, 2017
RegMed Investors’ (RMi) closing bell analysis, investors should reflect about what to do next
January 17, 2017
Lower open expected; RegMed Investors’ (RMi) pre-open, investors cool your heels
January 13, 2017
RegMed Investors’ (RMi) closing bell analysis, the week of hype was cut short
January 13, 2017
Higher open expected; RegMed Investors’ (RMi) pre-open, after a year of fluctuation, it’s time for managements to up their share pricing “game”
January 12, 2017
RegMed Investors’ (RMi) closing bell analysis, 2017 is starting off on a "fractured foot"
January 11, 2017
RegMed Investors’ (RMi) mid-day analysis, the sector gets a message nailed to the door …
January 11, 2017
Sangamo Therapeutics (SGMO) orphan drug designation to SB-318
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.